CANCER THERAPY

Biomarkers for neoadjuvant checkpoint blockade response in urothelial cancer

Activated CD8+ T cells in the tumor and cytotoxic T cell signature correlate with immune response in patients receiving neoadjuvant immunotherapy for treatment of muscle invasive bladder cancer.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: Immune biomarkers suggestive of response to neoadjuvant immunotherapy.

References

  1. 1.

    Bellmunt, J. & Bajorin, D. F. N. Engl. J. Med. 376, 2304 (2017).

    Article  Google Scholar 

  2. 2.

    Balar, A. V. et al. Lancet Oncol. 18, 1483–1492 (2017).

    CAS  Article  Google Scholar 

  3. 3.

    Mariathasan, S. et al. Nature 554, 544–548 (2018).

    CAS  Article  Google Scholar 

  4. 4.

    Teo, M.Y. et al. J. Clin. Oncol. JCO2017757740 (2018).

  5. 5.

    Powles, T. et al. https://doi.org/10.1038/s41591-019-0628-7 (2019).

  6. 6.

    Necchi, A. et al. J. Clin. Oncol. JCO1801148 (2018).

  7. 7.

    Hoimes, C. J et al. ESMO 2018 Congress, LBA33 (2018).

  8. 8.

    Huang, A. C. et al. Nat. Med. 25, 454–461 (2019).

    CAS  Article  Google Scholar 

  9. 9.

    Sjödahl, G. et al. Clin. Cancer Res. 18, 3377–3386 (2012).

    Article  Google Scholar 

  10. 10.

    Ayers, M. et al. J. Clin. Invest. 127, 2930–2940 (2017).

    Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Elizabeth Plimack.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Ghatalia, P., Plimack, E. Biomarkers for neoadjuvant checkpoint blockade response in urothelial cancer. Nat Med 25, 1650–1651 (2019). https://doi.org/10.1038/s41591-019-0645-6

Download citation